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Background: To report a rare case of a recurrence of spiradenoma that developed in the upper eyelid.
Case presentation: A 49-year-old woman who had a second recurrence of a tumor in the right palpebral conjunctiva
underwent local resection of the lesion with adjunctive cryotherapy to the surgical site. The tumor consisted of smooth,
round to oval nodular lesions approximately 1–3 mm in size with enlarged blood vessels. Histopathologically, the solid
and well-circumscribed nodule was located beneath the conjunctival epithelium. It was composed of cells with slightly
basophilic-to-clear cytoplasm and round-to-oval nuclei arranged in a trabecular pattern. Periodic acid-Schiff stain was
positive in the cytoplasm, and the staining disappeared after digesting by diastase. Many cells in mitosis were observed
throughout the tumor but no necrotic cells. Immunohistochemistry showed that the Ki-67 labeling index was 12%.
From these findings, we diagnosed this tumor as a recurrence of the spiradenoma. There has been no recurrence and
no signs of malignancy in the 6 months after the surgical excision.
Conclusion: Our findings indicate that a spiradenoma should be completely excised surgically because of malignant
transformation after repeated recurrences.
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Tumors arising from the sweat glands of the eyelids are
uncommon, and the differences in their structure have
given rise to much confusion [1-4]. A spiradenoma is a
type of sweat gland tumor which has a comparatively good
clinically course although it appears to be malignant [1,5].
A spiradenoma involving the eye or eyelid is rare [2,3].
We describe our findings in a patient with a recurrence of
spiradenoma that developed in the upper eyelid.
Case presentation
A 49-year-old woman visited a neighborhood eye clinic
complaining of a foreign body sensation and pain in her
right upper eyelid of several days duration. She was re-
ferred to our hospital for further evaluation and treat-
ment on the next day. Several years earlier, she had a
tumor excised from her right eyelid, and the tumor was
diagnosed as a spiradenoma. Our examination showed* Correspondence: sawadaa-gif@umin.ac.jp
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unless otherwise stated.that her best-corrected visual acuity (BCVA) was 20/30
OD and 20/20 OS. A round to oval-shaped nodule with
smooth borders was present in the right upper palpebral
conjunctiva (Figure 1A), which was thought to be the
same location of the previous tumor. The tumor was ex-
cised and evaluated histopathologically. The tumor cells
were arranged in intertwining bands just beneath the
conjunctiva. Two types of neoplastic cells were recog-
nized; one had a small dark nucleus representing an
undifferentiated cell, and the other was located at the
center of the bands with large pale nucleus (Figure 1B).
Levels of mitotic counts were low (0.3/10 HPF) and immu-
nohistochemical analysis showed that the Ki-67 labeling
index was 2.8% (Figure 2A). It was unclear if there were the
tumor cells still in the incisional margin of the slices.
One year later, she visited our hospital again complain-
ing of pain in the right eye. A nodule of approximately
1–3 mm in size accompanying by enlarged blood vessels
was observed at the right upper palpebral conjunctiva
(Figure 1C). This nodule was regarded as a recurrence. Pre-
auricular and cervical lymphadenopathy was not present.
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Figure 1 Clinical appearance of a spiradenoma in primary (A and B) and secondary tumors (C and D). A. A round to oval-shaped nodule
with smooth borders was present in the right upper palpebral conjunctiva. B. The tumor cells were arranged in intertwining bands just beneath
the conjunctiva. Two types of neoplastic cells were recognized; one had a small dark nucleus representing an undifferentiated cell, and the other
was located at the center of the bands with large pale nucleus. Levels of mitotic counts were low (0.3/10 HPF). Hematoxylin-eosin staining. C. The tumors
can be seen on the right upper palpebral conjunctiva, which was the slightly upper location of the previous tumor. Its surface is smooth. D. A solid and
well-circumscribed nodule can be seen beneath the conjunctival epithelium. It is composed of cells with slightly basophilic-to-clear cytoplasms and
round-to-oval nuclei and arranged in a trabecular pattern. Mitotic activity was increased (5.5/10 HPF) throughout the tumor with no necrosis.
Hematoxylin-eosin staining.
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normal findings were seen in the chest X-rays. The tumor
was excised with adjunctive cryotherapy and examined
histopathologically. The solid and well-circumscribed nod-
ule was located beneath the conjunctival epithelium. The
tumor cells were slightly basophilic with clear cytoplasm
and oval nuclei were arranged in a thick trabecular pattern
(Figure 1D). The two cell pattern, which was recognized
in the previous tumor, was inconspicuous. Mitotic activity
was increased (5.5/10HPF) throughout the tumor with no
necrosis (Figure 1D). Immunohistochemistry showed a
Ki-67 labeling index of 12.0% (Figure 2B). The tumor
stained weak positive for epithelial membrane antigen
(EMA), and negative for carcinoembryonic antigen (CEA),
low molecular-weight cytokeratin (CAM5.2), synaptophysin,and chromogranin A immunohistochemically. Periodic
acid-Schiff (PAS) stain was positive in the cytoplasm
(Figure 2C), but the positivity disappeared after diges-
tion by diastase (Figure 2D). The tumor was diagnosed
as a recurrence of the spiradenoma. There has been no
recurrence in the 6 months after the surgical removal
and cryotherapy.
Discussion
A spiradenoma is a tumor of the eccrine sweat glands that
arises as a solitary, intradermal, and painful nodule on the
chest or face and most frequently in early adulthood. Occa-
sionally, there may be multiple tumors [1,2,5]. It has been
well-characterized in the dermatological literature but not
in the ophthalmological literature probably because it is
Figure 2 Histopathology and immunohistochemical staining of a spiradenoma in primary (A) secondary tumors (B, C, and D). A. The
Ki-67 labeling index was 2.8%. B. The Ki-67 labeling index was 12%. C and D. Periodic acid-Schiff staining is positive in the cytoplasm (B), which
was digested by diastase (C).
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ledge, there has been no report of a primary spiradenoma
developing in the palpebral conjunctiva. In our case, the
tumor was considered to be a secondary spread of the ori-
ginal tumor at the primary site in the palpebral conjunctiva
of the eyelid. The majority of spiradenoma have a benign
course [2], and local recurrences have not been reported.
Considering our lesion was a local recurrence because of
an inadequate surgical removal, we treated the site of the
tumor excision with adjunctive cryotherapy to prevent
further recurrences.
Immunohistochemical study demonstrated that cytoker-
atin expression in eccrine spiradenoma was compared
with expression in normal eccrine glands and the tubular
structures are CEA positive [6,7]. In the present case, the
CAM5.2, and CEA were negative in the tumor cells and
the EMA was weakly positive. The immunohistochemical
results suggest that the tumor may inadequate differenti-
ate towards both the ductal and secretory segments of the
eccrine sweat glands.The differential diagnosis includes cylindroma, hidrade-
noma and sebaceoma. Dermal cylindroma and spirade-
noma in the same patient or in the same tumor mass are
well-represented in the literature [3,8]. Cylindroma differs
from spiradenoma by displaying islands of cells rimmed by
a basement membrane matrix and the presence of few lym-
phocytes [8]. Immunohistochemical reactivity for CAM5.2,
CEA, EMA, S-100, and vimentin in hidradenoma is charac-
teristic [9]. Because of the PAS-positivity and adipophilin
expression, our tumor mimicked a low grade malignant
tumor including sebaceous differentiations. Sebaceous dif-
ferentiations is defined as the presence of multiple cytoplas-
mic fat vacuoles and the positive staining of tumor cells for
EMA and negative staining for CEA [10,11].
Malignant changing of spiradenomas is unusual, and the
histology of malignant spiradenomas resembles squamous
metaplasia or very poorly differentiated pseudosarcomatous
spindle cell elements [5]. In cases of a malignant transform-
ation, the patient might die of systemic metastases several
months after the diagnosis [5]. Because our tumor had
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to 5.5/10 HPF) and had a trabecular or alveolar pattern, it
appeared to have a more aggressive pattern. The Ki-67
labeling index that is related to the prognostic features was
12% in our case. The tumor contained PAS-positive mater-
ial, which was identified as glycogen by its breakdown by
diastase. Thus, we diagnosed the tumor as a recurrence
spiradenoma from the clinical and pathological features of
the tumor and might be progressing to malignant changes.
Conclusions
We describe a recurrence of spiradenoma due to an
inadequate surgical excision at a rare site, the palpebral
conjunctiva. Although a spiradenoma is usually benign,
it may transform to a malignant spiradenoma, and thus
we are following this patient carefully.
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